![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/medium/ao1c06920_0003.gif)
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
![PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health](https://images.everydayhealth.com/images/lynparza-lengthens-survival-in-some-relapsed-ovarian-cancer-patients-722x406.jpg)
PARP Inhibitor Improves Odds for Women With Ovarian Cancer and More Cancer News From ASCO's Virtual Annual Meeting | Everyday Health
![Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics](https://els-jbs-prod-cdn.jbs.elsevierhealth.com/cms/attachment/bf9d0a08-b654-43d3-a093-b36672cae85a/gr1_lrg.jpg)
Effect of Itraconazole and Rifampin on the Pharmacokinetics of Olaparib in Patients With Advanced Solid Tumors: Results of Two Phase I Open-label Studies - Clinical Therapeutics
![Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors | SpringerLink Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors | SpringerLink](https://media.springernature.com/lw685/springer-static/image/art%3A10.1007%2Fs12325-015-0214-4/MediaObjects/12325_2015_214_Fig1_HTML.gif)
Effect of Food on the Pharmacokinetics of Olaparib after Oral Dosing of the Capsule Formulation in Patients with Advanced Solid Tumors | SpringerLink
![Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - ScienceDirect Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - ScienceDirect](https://ars.els-cdn.com/content/image/1-s2.0-S0305737221001298-gr2.jpg)
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - ScienceDirect
![Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library](https://ascpt.onlinelibrary.wiley.com/cms/asset/ae98dccf-b486-4a03-9b89-a4c9eded7cdf/cpt1103-fig-0002-m.jpg)
Physiologically Based Pharmacokinetic Modeling for Olaparib Dosing Recommendations: Bridging Formulations, Drug Interactions, and Patient Populations - Pilla Reddy - 2019 - Clinical Pharmacology & Therapeutics - Wiley Online Library
![Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews](https://www.cancertreatmentreviews.com/cms/asset/f3e3b15f-652d-476e-b830-11a8e3575b86/gr1.jpg)
Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations - Cancer Treatment Reviews
![Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance](https://www.mdpi.com/biomedicines/biomedicines-09-01512/article_deploy/html/images/biomedicines-09-01512-g001.png)
Biomedicines | Free Full-Text | Role of PARP in TNBC: Mechanism of Inhibition, Clinical Applications, and Resistance
![Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects](https://www.mdpi.com/pharmaceutics/pharmaceutics-14-01807/article_deploy/html/images/pharmaceutics-14-01807-g010.png)
Pharmaceutics | Free Full-Text | Fast-Fed Variability: Insights into Drug Delivery, Molecular Manifestations, and Regulatory Aspects
![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/large/ao1c06920_0006.jpeg)
Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega
![Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega Practical and Scalable Manufacturing Process for the Key Intermediate of Poly(ADP-Ribose) Polymerase Inhibitor Olaparib | ACS Omega](https://pubs.acs.org/cms/10.1021/acsomega.1c06920/asset/images/medium/ao1c06920_0005.gif)